Shrushma Loi

6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial

Helena Earl, Louise Hiller, Anne-Laure Vallier et al. · The Lancet · 2019 · 277 citations · Full text

PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results.

Helena Earl, Louise Hiller, Anne-Laure Vallier et al. · Journal of Clinical Oncology · 2018 · 70 citations

Breast Oncology, Clinical Endpoint, Population Health Sciences +16

Abstract GS2-06: Phase Ib/II study evaluating safety and efficacy of pembrolizumab and trastuzumab in patients with trastuzumab-resistant HER2-positive metastatic breast cancer: Results from the PANACEA (IBCSG 45-13/BIG 4-13/KEYNOTE-014) study

Shrushma Loi, Anita Giobbe-Hurder, Andrea Gombos et al. · Cancer Research · 2018 · 49 citations

Abstract Gs2-06, Breast Oncology, Immunology +18

Six versus 12 months’ adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT

Helena Earl, Louise Hiller, Anne-Laure Vallier et al. · Health Technology Assessment · 2020 · 20 citations · Full text

159O Prognostic value of tumour infiltrating lymphocytes in young triple negative breast cancer patients who did not receive adjuvant systemic treatment; by the PARADIGM study group

Vincent M. T. de Jong, Y. Wang, Mark Opdam et al. · Annals of Oncology · 2020 · 20 citations · Full text

Breast Oncology, Cancer Immunosurveillance, Medicine +10